Linear Diagnostics Limited

Linear Diagnostics Limited (LDL) is a United Kingdom based biotechnology and healthcare startup founded in 2011. Utilizing Linear Dichroism as a platform, LDL develops point-of-care tests for infectious diseases. The company's technology offers a novel approach to molecular diagnostics, enabling a wide range of tests to be conducted using a simple optical system. This innovative method provides several advantages over the current state of the art, allowing for the rapid detection of multiple targets with a single reagent. LDL's solution has applications across various high-value sectors, including health, food, defense, and security. LDL has forged strategic partnerships with end users such as clinical microbiology, food producers, and defense medicine, demonstrating the broad applicability of its technology. The company recently received a grant investment on 08 June 2023 from the National Institute for Health Research, a notable achievement that underscores the recognition and support for the innovative diagnostic solutions being developed by Linear Diagnostics Limited.